ウイルスベクター製造（研究用）の世界市場

ウイルスベクター製造（研究用）の世界市場は2030年までに40億米ドルに到達

2024年に17億米ドルと推定されるウイルスベクター製造（研究用）の世界市場は、2024～2030年の分析期間においてCAGR 15.0％で成長し、2030年には40億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるアデノ随伴ウイルスは、CAGR 17.0%を記録し、分析期間終了までに17億米ドルに達すると予測されます。レンチウイルスセグメントの成長率は、分析期間中CAGR16.2%と推定されます。

米国市場は4億7,210万米ドルと推定、中国はCAGR20.2%で成長すると予測

米国のウイルスベクター製造（研究用）市場は、2024年に4億7,210万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを20.2%として、2030年までに8億7,760万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.8％と13.5％と予測されています。欧州では、ドイツがCAGR 11.9%で成長すると予測されています。

世界のウイルスベクター製造（研究用）市場- 主要動向と促進要因のまとめ

なぜウイルスベクター生産は生物医学研究に不可欠なのか？

ウイルスベクター生産は、特に遺伝子治療、ワクチン、がん治療の開発において、生物医学研究の重要な要素となっています。ウイルスベクターは遺伝物質の送達システムとして機能し、科学者が細胞内に遺伝子を導入、改変、置換することで、疾病メカニズムの研究や標的療法の開発を可能にします。遺伝性疾患、感染症、がんの有病率の増加により、前臨床および臨床研究用の高品質ウイルスベクターの需要が高まっています。細胞治療や遺伝子治療の進歩に伴い、研究者はレンチウイルス、アデノ随伴ウイルス（AAV）、レトロウイルスなどのウイルスベクターを活用して、以前は治療不可能と考えられていた疾患に対する革新的な治療法を開発しています。現在進行中のmRNAベースのワクチンや免疫療法の開発は、ウイルスベクター製造の重要性をさらに浮き彫りにしています。研究者は創薬と開発を加速するために、スケーラブルで効率的な製造プロセスを必要としているからです。

どのような技術革新がウイルスベクター生産を変革しているのか？

ウイルスベクター生産の分野では、研究応用における効率性、拡張性、安全性を向上させる大きな進歩が見られます。最も注目すべき技術革新の一つは、懸濁細胞培養システムの使用であり、これによりバイオリアクターでの大規模なウイルスベクター生産が可能となり、コストの削減と一貫性の向上が実現しました。さらに、高収率のトランスフェクション試薬と最適化されたプラスミド設計の開発により、ウイルスベクターの力価が向上し、研究者は安定性を高めた高品質のベクターを生産できるようになりました。自動化とAIによるプロセスの最適化もまた、ばらつきを最小限に抑え、生産ワークフローを合理化することによって、ウイルスベクター製造に革命をもたらしています。CRISPRベースのゲノム編集ツールは、ウイルスベクター工学をさらに強化し、研究者がより精密で効率的な遺伝子導入システムを構築することを可能にしています。さらに、クロマトグラフィーや超遠心分離などの精製技術の向上により、ベクターの純度と効力が強化され、遺伝子治療研究においてより高い有効性が保証されています。

ウイルスベクター生産の拡大を制限している課題とは？

生物医学研究において重要な役割を担っているにもかかわらず、ウイルスベクター生産はスケーラビリティとアクセシビリティに影響するいくつかの課題に直面しています。主な障害の一つは、ウイルスベクター製造の複雑さであり、製造には特殊な細胞培養施設、バイオセーフティ・プロトコール、厳格な品質管理措置が必要です。特に、ウイルスベクターを大量に生産するインフラを持たない小規模の研究機関にとっては、高い生産コストと限られたスケーラビリティが依然として重要な障壁となっています。さらに、安全性への懸念や適正製造規範（GMP）の遵守など、ウイルスベクター生産に関連する規制上の課題も、研究から市場へのパイプラインを遅らせる可能性があります。ウイルスベクターの中には保存期間が短く、効力を維持するために特別な保存条件を必要とするものがあるため、安定性と保存の制限も課題となっています。これらの課題に対処するには、研究用ウイルスベクターをより広く利用できるようにするため、拡張性のある製造技術、標準化された規制の枠組み、費用対効果の高い生産戦略への継続的な投資が必要です。

ウイルスベクター製造（研究用）市場の成長を促進する要因は何か？

ウイルスベクター製造（研究用）市場の成長は、遺伝子治療に対する需要の高まり、ワクチン開発の進歩、生物医学研究への投資の増加など、いくつかの要因によって牽引されています。遺伝性疾患や感染症の蔓延が拡大していることから、革新的な治療アプローチの必要性が高まっており、研究開発者はウイルスベクターを用いた治療法の開発と改良に取り組んでいます。個別化医療と再生療法の拡大は、前臨床および臨床研究におけるウイルスベクターの採用をさらに加速させています。さらに、バイオテクノロジーに対する政府の資金援助や民間セクターの投資は、スケーラブルなウイルスベクター製造プラットフォームの開発を支援し、研究や医薬品開発のタイムラインの短縮を促進しています。CRISPRおよびゲノム編集技術の急速な進歩もまた、精密医療応用のための効率的な遺伝子導入ツールを研究者が求めていることから、市場の成長に寄与しています。ウイルスベクターの需要が増加し続ける中、継続的な技術の進歩とプロセスの最適化の取り組みが市場の拡大を促進し、遺伝子・細胞治療研究の継続的な進展を確実なものにすると予想されます。

セグメント

ベクターの種類（アデノ随伴ウイルス、レンチウイルス、アデノウイルス、レトロウイルス、その他）、用途（細胞・遺伝子治療開発、ワクチン開発、医薬品・バイオ医薬品探索、バイオメディカル研究）、最終用途（医薬品・バイオ医薬品企業、研究機関）

調査対象企業の例

• AGC Biologics
• Batavia Biosciences
• BioNTech IMFS GmbH
• Catalent Inc.
• Cobra Biologics（Charles River Laboratories）
• FUJIFILM Diosynth Biotechnologies
• Genezen
• Lonza Group
• Merck KGaA
• Miltenyi Biotec
• Novasep Holdings SAS
• Oxford Biomedica
• REGENXBIO Inc.
• SIRION Biotech GmbH
• Takara Bio Inc.
• Thermo Fisher Scientific
• uniQure N.V.
• Virovek
• Waisman Biomanufacturing
• WuXi AppTec

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Viral Vector Production (Research-Use) Market to Reach US$4.0 Billion by 2030

The global market for Viral Vector Production (Research-Use) estimated at US$1.7 Billion in the year 2024, is expected to reach US$4.0 Billion by 2030, growing at a CAGR of 15.0% over the analysis period 2024-2030. Adeno-associated Virus, one of the segments analyzed in the report, is expected to record a 17.0% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Lentivirus segment is estimated at 16.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$472.1 Million While China is Forecast to Grow at 20.2% CAGR

The Viral Vector Production (Research-Use) market in the U.S. is estimated at US$472.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$877.6 Million by the year 2030 trailing a CAGR of 20.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.8% and 13.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.9% CAGR.

Global Viral Vector Production (Research-Use) Market - Key Trends & Drivers Summarized

Why Is Viral Vector Production Critical for Biomedical Research?

Viral vector production has become a crucial component of biomedical research, particularly in the development of gene therapies, vaccines, and cancer treatments. Viral vectors serve as delivery systems for genetic material, enabling scientists to introduce, modify, or replace genes within cells to study disease mechanisms and develop targeted therapies. The increasing prevalence of genetic disorders, infectious diseases, and cancer has fueled the demand for high-quality viral vectors for preclinical and clinical research. With advancements in cell and gene therapy, researchers are leveraging viral vectors such as lentiviruses, adeno-associated viruses (AAVs), and retroviruses to develop innovative treatments for conditions that were previously considered untreatable. The ongoing development of mRNA-based vaccines and immunotherapies has further highlighted the importance of viral vector production, as researchers require scalable and efficient manufacturing processes to accelerate drug discovery and development.

What Technological Innovations Are Transforming Viral Vector Production?

The field of viral vector production has seen significant advancements, improving efficiency, scalability, and safety in research applications. One of the most notable innovations is the use of suspension cell culture systems, which enable large-scale viral vector production in bioreactors, reducing costs and improving consistency. Additionally, the development of high-yield transfection reagents and optimized plasmid designs has enhanced viral vector titers, allowing researchers to produce higher-quality vectors with increased stability. Automation and AI-driven process optimization are also revolutionizing viral vector manufacturing by minimizing variability and streamlining production workflows. CRISPR-based genome editing tools are further enhancing viral vector engineering, enabling researchers to create more precise and efficient gene delivery systems. Moreover, improvements in purification technologies, such as chromatography and ultracentrifugation, have enhanced vector purity and potency, ensuring higher efficacy in gene therapy research.

What Challenges Are Limiting the Expansion of Viral Vector Production?

Despite its critical role in biomedical research, viral vector production faces several challenges that impact scalability and accessibility. One of the primary obstacles is the complexity of manufacturing viral vectors, as production requires specialized cell culture facilities, biosafety protocols, and rigorous quality control measures. High production costs and limited scalability remain key barriers, particularly for smaller research institutions that lack the infrastructure to produce viral vectors in large quantities. Additionally, regulatory challenges associated with viral vector production, including safety concerns and compliance with good manufacturing practices (GMP), can slow down the research-to-market pipeline. Stability and storage limitations also pose a challenge, as some viral vectors have short shelf lives, requiring specialized storage conditions to maintain potency. Addressing these challenges requires continued investment in scalable manufacturing technologies, standardized regulatory frameworks, and cost-effective production strategies to ensure broader accessibility of viral vectors for research use.

What Factors Are Driving the Growth of the Viral Vector Production (Research-Use) Market?

The growth in the viral vector production (research-use) market is driven by several factors, including the rising demand for gene therapies, advancements in vaccine development, and increasing investments in biomedical research. The growing prevalence of genetic disorders and infectious diseases has fueled the need for innovative treatment approaches, prompting researchers to develop and refine viral vector-based therapies. The expansion of personalized medicine and regenerative therapies has further accelerated the adoption of viral vectors in preclinical and clinical research. Additionally, government funding and private sector investments in biotechnology have supported the development of scalable viral vector manufacturing platforms, facilitating faster research and drug development timelines. The rapid advancement of CRISPR and genome-editing technologies has also contributed to market growth, as researchers seek efficient gene delivery tools for precision medicine applications. As demand for viral vectors continues to rise, ongoing technological advancements and process optimization efforts are expected to drive market expansion, ensuring the continued progress of gene and cell therapy research.

SCOPE OF STUDY:

The report analyzes the Viral Vector Production (Research-Use) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vector Type (Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus, Others); Application (Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery, Biomedical Research); End-Use (Pharma & Biopharma Companies, Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AGC Biologics
• Batavia Biosciences
• BioNTech IMFS GmbH
• Catalent Inc.
• Cobra Biologics (Charles River Laboratories)
• FUJIFILM Diosynth Biotechnologies
• Genezen
• Lonza Group
• Merck KGaA
• Miltenyi Biotec
• Novasep Holdings SAS
• Oxford Biomedica
• REGENXBIO Inc.
• SIRION Biotech GmbH
• Takara Bio Inc.
• Thermo Fisher Scientific
• uniQure N.V.
• Virovek
• Waisman Biomanufacturing
• WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Viral Vector Production (Research-Use) - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Expanding Role of Viral Vectors in Gene Therapy Research Throws the Spotlight On Custom Vector Manufacturing
  • Surging Demand for Preclinical Gene Delivery Studies Drives Adoption of Scalable Research-Grade Viral Vectors
  • Growth in Academic and Translational Research Accelerates Demand for Customizable and Cost-Efficient Viral Platforms
  • Increased Funding for Cell and Gene Therapy Projects Expands Addressable Market Opportunity for Research-Use Vectors
  • Technological Advances in Transfection and Packaging Protocols Strengthen Business Case for High-Yield Production
  • Rising Use of Adeno-Associated and Lentiviral Vectors Spurs Growth in Non-GMP Research Settings
  • Integration of CRISPR and Gene Editing Applications Drives Demand for High-Fidelity Viral Vectors
  • Emergence of Modular Vector Design Technologies Enhances Flexibility and Reduces Turnaround Time
  • Growing Adoption of Suspension Cell Culture Systems Accelerates Shift Toward Scalable Manufacturing Platforms
  • Advancements in Purification and Concentration Methods Strengthen Competitive Advantage in Research-Use Markets
  • Expansion of Contract Research Organizations (CROs) Bolsters Outsourced Vector Development Capabilities
  • Shift Toward Personalized and Targeted Research Models Drives Demand for Custom Viral Constructs
  • Regulatory Loosening for Research-Only Vectors Streamlines Academic and Preclinical Development Pipelines
  • Increased Interdisciplinary Research Collaborations Propel Demand for Versatile Viral Vector Toolkits
  • Adoption of High-Throughput Screening Technologies Expands Use of Viral Vectors in Functional Genomics
  • Emerging Interest in Non-Human Primate Models Drives Demand for Species-Specific Viral Vector Solutions
  • Transition from 2D to 3D Cell Culture Systems Spurs Innovation in Vector Delivery Mechanisms
  • Growing Complexity of Experimental Therapeutics Throws the Spotlight On Multi-Gene Delivery Vectors
  • Rising Emphasis on Safety and Transduction Efficiency Strengthens Demand for Next-Gen Research Vectors
  • Widening Gap Between Research-Grade and GMP-Grade Vector Capabilities Creates Strategic Differentiation Opportunities
  • Globalization of Research and Cross-Border Collaborations Drives Growth in Multi-Regional Vector Supply Chains
  • Expansion of Incubator Labs and Biotech Accelerators Generates New Market for Ready-to-Use Research Vectors
  • Growing Public and Private Investment in Viral Vector Research Programs Fuels Long-Term Market Sustainability
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Viral Vector Production (Research-Use) Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Viral Vector Production (Research-Use) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Viral Vector Production (Research-Use) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Adeno-associated Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Adeno-associated Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Adeno-associated Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Lentivirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Lentivirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Lentivirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Adenovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retrovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retrovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Retrovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cell & Gene Therapy Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cell & Gene Therapy Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cell & Gene Therapy Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Vaccine Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Vaccine Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Vaccine Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pharma & Biopharma Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pharma & Biopharma Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Pharma & Biopharma Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Biomedical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• JAPAN
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• CHINA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• EUROPE
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Viral Vector Production (Research-Use) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Viral Vector Production (Research-Use) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• FRANCE
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• GERMANY
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Viral Vector Production (Research-Use) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Viral Vector Production (Research-Use) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• INDIA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Viral Vector Production (Research-Use) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Viral Vector Production (Research-Use) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Viral Vector Production (Research-Use) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Viral Vector Production (Research-Use) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030
• AFRICA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Viral Vector Production (Research-Use) by Vector Type - Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Viral Vector Production (Research-Use) by Vector Type - Percentage Breakdown of Value Sales for Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus and Others for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Viral Vector Production (Research-Use) by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Viral Vector Production (Research-Use) by End-Use - Percentage Breakdown of Value Sales for Pharma & Biopharma Companies and Research Institutes for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Viral Vector Production (Research-Use) by Application - Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Viral Vector Production (Research-Use) by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery and Biomedical Research for the Years 2015, 2025 & 2030

IV. COMPETITION